# Ne oldu?

The U.S. Food and Drug Administration (FDA) announced accelerated approval of Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy developed for the treatment of Glycogen Storage Disease Type Ia (GSDIa). This is the first approved therapy for the condition. The approval allows the therapy to be used to reduce daily cornstarch intake as an adjunct to nutritional management in adults and pediatric patients aged 8 years and older.

# Ayrıntılar

GSDIa is a rare, inherited genetic disorder caused by a deficiency of the enzyme glucose-6-phosphatase. This deficiency leads to dangerous drops in blood sugar during fasting, requiring patients to adhere to a strict, life-long dietary regimen that typically includes consuming cornstarch every few hours to maintain stable glucose levels. Genglycos works via gene therapy to address the underlying metabolic defect. The FDA's approval was based on clinical trial data demonstrating that Genglycos helps reduce daily cornstarch intake. Because the approval was based on a surrogate endpoint—reduction of cornstarch intake—rather than direct clinical outcomes such as reduced hypoglycemia or improved growth, the manufacturer is required to conduct additional post-approval trials to confirm the therapy's clinical benefit.

# Neden önemli?

This approval represents a significant milestone for patients with GSDIa, who previously had limited treatment options reliant on stringent dietary control. The availability of a gene therapy option offers the potential to improve quality of life by reducing the burden of constant dietary management. However, the accelerated nature of the approval means that long-term safety and efficacy data are still pending, and the medical community will be awaiting the results of the required confirmatory trials.

# Sırada ne var?

The FDA has mandated that the manufacturer complete additional clinical trials to verify Genglycos's effectiveness in providing clinical benefit beyond the surrogate endpoint of cornstarch reduction. Patients and caregivers should consult with metabolic specialists to understand how this therapy fits into their overall management plan and to monitor for any long-term effects as real-world data emerges.